CELC heads into its November earnings window with short sellers adding positions at a measured but persistent pace, even as the Street holds overwhelmingly bullish targets well above the current price.
Short interest has climbed steadily through September and now accounts for nearly 25% of the free float, up roughly 20% over the past month and about 4.6% on the week alone. That is a meaningful rebuild. The FINRA fortnightly confirms 11.36 million shares short with a days-to-cover reading of 12.5, meaning any forced unwind would take nearly three weeks at average volume. The ORTEX short score is 75.6, placing CELC firmly in the high-conviction-short category, though it has eased slightly from the 77.3 peak hit earlier in the month. Borrow availability tells a less alarming story: availability stands at 174% of short interest, well above the 52-week trough of 69%, so there is no supply squeeze in the lending market. Cost to borrow remains low at 0.65%, even after a sharp jump this week from 0.38%. The borrow is cheap and available, which means the short thesis is being expressed through conviction rather than technical forced-covering pressure.
Options traders are not adding to the bearish pile. The put/call ratio has been drifting lower through September, settling at 0.51 against a 20-day average of 0.56, and is running below its long-run mean rather than above it. The PCR touched a 52-week high of 1.04 in mid-August, around the last earnings print, but has since unwound almost entirely. That divergence is the note: short sellers are building while options traders are becoming more relaxed about downside protection, two markets pointing in different directions.
The Street remains firmly bullish but has been trimming targets since August. Every analyst covering the stock holds a Buy or equivalent, and the mean price target is just above $159, implying roughly 106% upside from the current $77.38. That gap is striking, though targets have been coming down. JP Morgan initiated at Overweight with a $157 target on September 17, a fresh vote of confidence. Needham trimmed its target this morning from $140 to $134, the second consecutive cut after reducing from $157 to $140 in August following the Q2 print. Stifel similarly cut from $175 to $150 in August. The pattern is uniform: no one is capitulating on the rating, but nearly every firm has nudged estimates lower after Q2. Factor scores reinforce the bullish-case-meets-execution-risk tension: analyst recommendation divergence ranks in the 92nd percentile (extremely positive consensus relative to the market), while the short score sits in the bottom 7th percentile, and EPS momentum scores are weak at 7 and 15 on the 30-day and 90-day windows. Forward EPS estimates are improving year-over-year, earning an 81st percentile rank there, but near-term momentum has stalled.
Baker Bros. Advisors remains a central figure in the ownership story. The firm holds roughly 9.84% of shares per the latest filing and filed a Schedule 13D in July, meaning it carries activist-intent status on the SEC register. That said, Baker Bros. sold 3.1 million shares on July 14 at $102.50, generating roughly $318 million in proceeds. Those trades dominate the 90-day insider net, which stands at minus 3.1 million shares worth approximately $318 million. The August executive compensation grants to CEO Brian Sullivan, CFO Vicky Hahne and CSO Lance Laing are all classified as awards (transaction code A), not open-market purchases, so they carry no conviction read. A second Schedule 13D filer, Growth Equity Opportunities 18 VGE, reduced its stake from 6.3% to 4.9% in its March amendment, falling below the 5% threshold where further disclosure may not be required. Perceptive Advisors, RTW Investments and Soleus Capital all added modestly in Q2 on the passive 13G register, providing some counterweight to the Baker Bros. exit.
The bear case is pointed: Celcuity faces intensifying competition in the HR+/HER2- metastatic breast cancer market, and gedatolisib's ability to sustain peak sales projections above $2.5 billion is unproven. A commercial launch is expected in late Q3 2026, meaning real-world prescription data will begin accumulating in the weeks ahead. The earnings print is scheduled for November 13. That event will be the first opportunity for the company to report any early commercial traction. With a quarter of the float short, a bullish Street sitting far above the current price, and a major institutional seller having exited at prices 30% higher, the November print carries more weight than a typical quarterly update.
What to watch: whether early commercial data from the gedatolisib launch appears in management commentary ahead of November, and whether Baker Bros. files another 13D amendment reflecting any further change in its position.
See the live data behind this article on ORTEX.
Open CELC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
